Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses (Tables)

v3.19.1
Accrued Expenses (Tables)
 3 Months Ended
Mar. 31, 2019
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consisted of the following:

 

    March 31, 2019     December 31, 2018  
Accrued clinical operations and trials costs   $ 9,585,065     $ 4,914,881  
Accrued product development costs     3,703,548       2,222,093  
Accrued compensation     1,327,756       2,253,621  
Accrued other     947,484       460,596  
Total   $ 15,563,853     $ 9,851,191